paclitaxel has been researched along with Ventricular Dysfunction, Left in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 18 (64.29) | 29.6817 |
| 2010's | 9 (32.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, CT; Eaton, A; Hudis, CA; Liu, JE; Oeffinger, KC; Singh, JC; Steingart, RM; Wang, R; Yu, AF | 1 |
| Atkins, JN; Biggs, DD; Brufsky, AM; Cecchini, RS; Fehrenbacher, L; Flynn, PJ; Ganz, PA; Geyer, CE; Gross, HM; Jeong, JH; Mamounas, EP; Polikoff, J; Rastogi, P; Romond, EH; Seay, TE; Swain, SM; Wade, JL; Wahl, TA; Wolmark, N; Zapas, JL | 1 |
| Braunstein, LZ; Cahlon, O; Dang, CT; Eaton, A; Ho, AY; Lee Chuy, K; Liu, JE; Mara, E; Oeffinger, KC; Steingart, RM; Thor, ME; Yu, AF | 1 |
| Baliulis, G; Corbett, S; Curzen, N; Kaarne, M; Olsen, S; Rawlins, J; Roubelakis, A | 1 |
| Albain, K; Burstein, HJ; Carey, LA; Dang, C; Ellis, M; Groarke, J; Guo, H; Hudis, C; Krop, I; Marcom, K; Miller, K; Moslehi, J; Moy, B; Najita, J; Rugo, H; Shapira, I; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, D | 1 |
| Chamorey, E; Ferrero, JM; Milano, G | 1 |
| Beer, LA; Domchek, S; Kossenkov, AV; Ky, B; Liu, Q; Luning Prak, E; Speicher, DW | 1 |
| Gokoz-Dogu, G; Saricopur, A; Senol, H; Yaylali, YT; Yurtdas, M | 1 |
| Abbate, A; Appleton, DL; Cowley, MJ; Di Sciascio, G; Goudreau, E; Lipinski, MJ; Nusca, A; Varma, A; Vetrovec, GW; Wittkamp, MJ | 1 |
| Chen, YH; Li, J; Liang, D; Liu, Y; Peng, L; Xiao, J; Zhang, H; Zhao, H; Zhou, Z | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Dakhil, SR; Davidson, NE; Gersh, BJ; Ingle, JN; Jaffe, AS; Kaufman, PA; Martino, S; Perez, EA; Rodeheffer, RJ; Suman, VJ | 1 |
| Hudis, C; Keefe, D; Lieberman, G; Paton, V; Seidman, A; Tripathy, D | 1 |
| Albertal, M; Balino, PP; Belardi, JA; Berrocal, D; Cura, F; Fava, C; Grinfeld, L; Mendiz, O; Padilla, L; Pascua, JA; Solioz, G | 1 |
| Jang, Y; Jeon, DW; Kim, BO; Ko, YG; Kwon, HM; Lee, SH; Park, SH; Ryu, SK; Yang, JY; Yoon, JH | 1 |
| Brown, A; Bryant, J; Ewer, M; Fehrenbacher, L; Geyer, CE; Keefe, D; Mamounas, EP; Rastogi, P; Romond, E; Seay, TE; Shannon, RP; Swain, SM; Tan-Chiu, E; Vogel, VG; Wolmark, N; Yothers, G | 1 |
| Benassi, A; Ewing, LG; Gioia, G; Levite, HA; Matthai, W; Rana, H | 1 |
| Carey, LA; Collichio, F; Dees, EC; Dressler, L; Gatti, L; Graham, ML; Ivanova, A; Kelly, H; Kimmick, G; Sawyer, L | 1 |
| Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Park, KH; Park, SJ; Park, SW | 1 |
| Thomas, M | 1 |
| Benassi, A; Dralle, J; Gillin, K; Gioia, G; Gioia, MF; Matthai, W; White, J | 1 |
| Currie, V; D'Andrea, G; Dang, C; Dickler, M; Drullinsky, P; Fornier, M; Gilewski, T; Hudis, C; Lake, D; Mills, N; Moynahan, ME; Norton, L; Panageas, K; Robson, M; Seidman, A; Sklarin, N; Steingart, R; Sugarman, S; Troso-Sandoval, T; Wasserheit-Leiblich, C | 1 |
| Hoefnagel, CA; ten Bokkel Huinink, WW; Valdés Olmos, RA | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM | 1 |
| Bdolah-Abram, T; Burtness, BA; D'Andrea, E; Gollerkeri, A; Lee, FA; Psyrri, A; Rose, M | 1 |
| Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G | 1 |
| Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI | 1 |
10 trial(s) available for paclitaxel and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitax
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Survivors; Cardiovascular System; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left | 2004 |
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left | 2004 |
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Heart; Heart Diseases; Heart Failure; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Incidence; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2005 |
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; North Carolina; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Gene Amplification; Heart; Heart Failure; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2008 |
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Synergism; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiotherapy; Risk; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
18 other study(ies) available for paclitaxel and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Echocardiography, Doppler; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Trastuzumab; Ventricular Dysfunction, Left | 2019 |
Coronary artery rupture caused by stent infection: a rare complication.
Topics: Angina, Unstable; Anti-Bacterial Agents; Chest Pain; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Drug-Eluting Stents; Emergencies; Floxacillin; Fusidic Acid; Humans; Internal Mammary-Coronary Artery Anastomosis; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis-Related Infections; Rupture, Spontaneous; Staphylococcal Infections; Ultrasonography; Ventricular Dysfunction, Left | 2015 |
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome; United States; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult | 2016 |
Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cardiomyopathies; Case-Control Studies; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Heart Failure; Humans; Immunoglobulin E; Immunoglobulin G; Middle Aged; Paclitaxel; Proteomics; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Young Adult | 2016 |
Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Breast Neoplasms; Case-Control Studies; Cyclophosphamide; Diastole; Doxorubicin; Echocardiography; Female; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Systole; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Paclitaxel; Retrospective Studies; Sirolimus; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2008 |
Taxol, a microtubule stabilizer, improves cardiac contractile function during ischemia in vitro.
Topics: Animals; Calcium Signaling; Cells, Cultured; Electron Transport Chain Complex Proteins; Heart Failure; Heart Ventricles; Homeostasis; In Vitro Techniques; Male; Microtubules; Mitochondria, Heart; Myocardial Contraction; Myocardial Ischemia; Myocytes, Cardiac; Paclitaxel; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Time Factors; Tubulin Modulators; Ventricular Dysfunction, Left | 2010 |
Use of drug-eluting stents for the treatment of in-stent restenosis in routine clinical practice.
Topics: Aged; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Practice Patterns, Physicians'; Retrospective Studies; Sirolimus; Stents; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Sirolimus- versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Sirolimus; Stents; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction.
Topics: Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Cardiomyopathies; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Female; Follow-Up Studies; Heart Failure; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Paclitaxel; Prosthesis Design; Research Design; Severity of Illness Index; Sirolimus; Stents; Stroke Volume; Survival Rate; Treatment Outcome; United States; Ventricular Dysfunction, Left | 2006 |
Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Korea; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Outcome Assessment, Health Care; Paclitaxel; Prospective Studies; Prosthesis Design; Sirolimus; Stents; Ventricular Dysfunction, Left | 2006 |
Revascularization for ischemic LV dysfunction: stents or surgery?
Topics: Angioplasty, Balloon, Coronary; Cardiomyopathies; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Bypass; Humans; Myocardial Ischemia; Paclitaxel; Patient Selection; Prosthesis Design; Radiography; Severity of Illness Index; Sirolimus; Stents; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2007 |
Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiomyopathies; Cardiovascular Agents; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Paclitaxel; Prosthesis Design; Research Design; Retrospective Studies; Severity of Illness Index; Sirolimus; Stents; Time Factors; Treatment Outcome; United States; Ventricular Dysfunction, Left | 2007 |
Cardiac dysfunction in cancer patients receiving paclitaxel.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Female; Heart Failure; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stroke Volume; Ventricular Dysfunction, Left | 1998 |
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Rate; Ventricular Dysfunction, Left | 2000 |
Docetaxel induced cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left | 2001 |